Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

Gan & Lee Pharmaceuticals has initiated Phase I trials for GZC8072, a once-weekly oral GLP-1 peptide aiming to treat type 2 diabetes and obesity, using proprietary technologies to extend half-life and improve oral bioavailability.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a new competitor in oral diabetes drugs pushing once-weekly dosing, reshaping convenience expectations and adherence in GLP-1 therapies. Move quickly to evaluate peptide bioavailability innovations to stay relevant against this distinct approach to weekly oral dosing.

◆ Coverage

1 source · 11 Sep 2026

◆ Related on Wire

◆ Topics

Biotechglp-1oral-peptidediabetesobesityphase-ichina